Pathios Therapeutics Secures $25M in Series B Funding for Cancer Drug Development.

Telomir Pharmaceuticals Reveals Promising Early Results for Anti-Aging Medication Telomir-1 at a Press Event in Washington, D.C.

Principles of Sustained and Controlled Drug Release for Extended Efficacy and Stable Blood Levels.

Subcutaneous Ocrevus, by Genentech, Shows Almost Total Control of Clinical Relapses and Brain Lesions Over a Year in Progressive and Relapsing MS Cases.

In March, British pharmaceutical giant AstraZeneca announced its intention to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing innovative therapies for rare endocrine diseases.

Ventus Therapeutics Releases Findings of Phase 1 Study for VENT-02, an Innovative Oral Brain-Targeting NLRP3 Inhibitor.

After a drug clinical trial is approved, it must commence within three years from the date of approval.

Press Announcement: Latest 48-week stage 2 findings on frexalimab indicate promising consistent effectiveness in treating multiple sclerosis.

April 19th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Alvotech and Teva have received FDA clearance in the U.S. for their product SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab).

Comparing Synthetic and Recombinant Peptide Production: Processes, Applications, Costs, and Scalability.

Eloxx Pharmaceuticals, Inc. announced recent developments in their programs for ELX-02 and ZKN-013, highlighting the Orphan Drug Designation awarded to ELX-02.